<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01721941</url>
  </required_header>
  <id_info>
    <org_study_id>TH302 TACE</org_study_id>
    <nct_id>NCT01721941</nct_id>
  </id_info>
  <brief_title>TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma</brief_title>
  <official_title>A Phase I Dose Escalation Study of TH-302 Plus Doxorubicin Delivered by Trans-Arterial Chemoembolization (TACE) in Patients With Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Clinic Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Threshold Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Scripps Clinic Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this phase I dose escalation study is to determine the maximum&#xD;
      tolerated dose of TH-302 when administered with doxorubicin via trans-arterial&#xD;
      chemo-embolization (TACE) in patients with hepatocellular carcinoma (HCC) who are not&#xD;
      transplant candidates and have unresectable disease. HCC is the second leading cause of&#xD;
      worldwide cancer death and is generally incurable without liver transplant. TACE can convert&#xD;
      about 40% of these patients to transplant candidates. Additionally, in non-transplant HCC&#xD;
      patients, TACE confers statistical improvements in overall survival. Selective HCC arterial&#xD;
      catheterization during TACE allows for the delivery of concentrated drugs to the liver tumor&#xD;
      but the optimal TACE chemotherapy regimen has not yet been determined. TH-302 is a hypoxia&#xD;
      inducible agent that can be activated in the hypoxic environment induced by TACE.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Transarterial chemoembolization (TACE) is the major modality utilized for tumor downstaging&#xD;
      for transplant and for local therapy in non-transplant patients. This procedure allows&#xD;
      delivery of concentrated drugs to the tumor, followed by embolization that eliminates its&#xD;
      blood supply creating an environment of hypoxia. The process induces tumor ischemia, while&#xD;
      achieving a drug concentration in the tumor 10 to 25 times greater than can be achieved by&#xD;
      infusion.&#xD;
&#xD;
      A hypoxic microenvironment is a characteristic of many solid tumors including hepatocellular&#xD;
      cancer, further induced by TACE. The hypoxia-activated prodrug, TH-302, is designed to&#xD;
      selectively physiologically target the hypoxic microenvironment. While doxorubicin and&#xD;
      cisplatin have been used as the drugs in TACE among other agents, none have stood out as the&#xD;
      optimal agent in targeting HCC. Because of the action of TH-302 in hypoxia, this agent has a&#xD;
      mechanistic advantage as a agent in TACE.&#xD;
&#xD;
      The current study is designed to assess the potential therapeutic benefit of adding TH-302 to&#xD;
      the standard doxorubicin based TACE regimen in patients with advanced hepatocellular&#xD;
      carcinomas.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose of TH-302 use in TACE</measure>
    <time_frame>33 weeks</time_frame>
    <description>Maximum tolerated dose (MTD) of TH-302 when co-administered with doxorubicin via TACE in patients with advanced hepatocellular cancer will be assessed with a Fibonacci (3+3) dose escalation design.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>12 months</time_frame>
    <description>Assess overall response rate using standard RECIST criteria measured by triple phase CT or MRI at least 6 weeks post TACE administration</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Phase I dose level -1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 25mg; Doxorubicin 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 50mg; doxorubicin 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase I Dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 100mg; doxorubicin 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1 Dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TH-302 150mg; Doxorubicin 50mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I Dose level -1</intervention_name>
    <description>The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).</description>
    <arm_group_label>Phase I dose level -1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I dose level 1</intervention_name>
    <description>The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).</description>
    <arm_group_label>Phase I Dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I Dose level 2</intervention_name>
    <description>The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).</description>
    <arm_group_label>Phase I Dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phase I Dose level 3</intervention_name>
    <description>The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).</description>
    <arm_group_label>Phase 1 Dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age&#xD;
&#xD;
          -  Ability to understand the purposes and risks of the study and has signed a written&#xD;
             informed consent form approved by the investigator's IRB/Ethics Committee&#xD;
&#xD;
          -  Patients with hepatocellular carcinoma with either:&#xD;
&#xD;
               1. liver limited disease who are not transplant candidates as they fall outside of&#xD;
                  Milan criteria, but may be eligible for transplant after successful downstaging&#xD;
                  with TACE&#xD;
&#xD;
               2. liver limited disease who satisfy Milan criteria, but are at risk of falling out&#xD;
                  of Milan criteria before they receive a liver transplant&#xD;
&#xD;
               3. non-transplantable HCC but with liver limited or metastatic disease that requires&#xD;
                  local TACE therapy&#xD;
&#xD;
          -  Measurable disease by modified RECIST criteria (at least one target lesion outside of&#xD;
             previous radiation fields)&#xD;
&#xD;
          -  ECOG performance status of 2 or less&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Childs-Pugh Class A or B&#xD;
&#xD;
          -  HCC amenable to TACE&#xD;
&#xD;
          -  Patent main portal vein (thrombosis of portal vein branch not exclusionary)&#xD;
&#xD;
          -  Acceptable liver function:&#xD;
&#xD;
          -  Bilirubin &lt; 2 mg/dL&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &lt; 5 x ULN is allowed&#xD;
&#xD;
          -  Acceptable renal function:&#xD;
&#xD;
          -  Serum creatinine &lt; 1.5 ULN&#xD;
&#xD;
          -  Acceptable hematologic status (without hematologic support for TACE #1):&#xD;
&#xD;
          -  ANC &gt; 500 cells/μL&#xD;
&#xD;
          -  Platelet count &gt; 50,000/μL&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association (NYHA) Class III or IV, cardiac disease, myocardial&#xD;
             infarction within 6 months prior to Day 1, unstable arrhythmia or symptomatic&#xD;
             peripheral arterial vascular disease&#xD;
&#xD;
          -  Known brain, leptomeningeal or epidural metastases (unless treated and well controlled&#xD;
             for &gt;=3 months)&#xD;
&#xD;
          -  Previously treated malignancies, except for adequately treated non-melanoma skin&#xD;
             cancer, in situ cancer, or other cancer from which the subject has been disease-free&#xD;
             for at least 5 years&#xD;
&#xD;
          -  Severe chronic obstructive or other pulmonary disease with hypoxemia (requires&#xD;
             supplementary oxygen, symptoms due to hypoxemia or oxygen saturation &lt;90% by pulse&#xD;
             oximetry after a 2 minute walk) or in the opinion of the investigator any&#xD;
             physiological state likely to cause systemic or regional hypoxemia&#xD;
&#xD;
          -  Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1, without&#xD;
             complete recovery&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Sorafenib within the previous 4 weeks or the intention to initiate sorafenib while on&#xD;
             study&#xD;
&#xD;
          -  Poor liver function as indicated by serum bilirubin &gt; 2 mg/dL, Child-Pugh Class C,&#xD;
             severe coagulopathy (INR &gt; 2) not correctable with vitamin K, or active hepatic&#xD;
             encephalopathy&#xD;
&#xD;
          -  Main portal vein occlusion&#xD;
&#xD;
          -  Liver rupture or tumor penetration of liver capsule&#xD;
&#xD;
          -  Tumor invasion of biliary system with biliary obstruction&#xD;
&#xD;
          -  Severe cytopenias, including ANC &lt; 500 cells/μL, Hemoglobin &lt; 8 g/dL, or platelets &lt;&#xD;
             50,000/μL&#xD;
&#xD;
          -  Subjects who have exhibited allergic reactions to a structural compound, biological&#xD;
             agent similar to TH-302&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  Concomitant disease or condition that could interfere with the conduct of the study,&#xD;
             or that would, in the opinion of the investigator, pose an unacceptable risk to the&#xD;
             subject in this study&#xD;
&#xD;
          -  Unwillingness or inability to comply with the study protocol for any reason&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darren S Sigal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alain Perez</last_name>
    <phone>858-554-9379</phone>
    <email>Perez.Alain@scrippshealth.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Alain Perez</last_name>
      <phone>858-554-8937</phone>
      <email>Perez.Alain@scrippshealth.org</email>
    </contact>
    <investigator>
      <last_name>Darren S Sigal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>October 8, 2012</study_first_submitted>
  <study_first_submitted_qc>November 2, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 6, 2012</study_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 4, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>liver cancer</keyword>
  <keyword>hepatoma</keyword>
  <keyword>TACE</keyword>
  <keyword>transarterial chemoembolization</keyword>
  <keyword>TH302</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

